Observational studyBMC infectious diseases2026
Baloxavir marboxil versus oseltamivir for influenza A in children aged 5 years and older: a community-based prospective cohort study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInfluenza A places a substantial burden on children. Real-world comparisons of antiviral regimens in community pediatric settings remain limited. This prospective cohort study compared the effectiveness and safety of a single-dose baloxavir marboxil regimen with a standard five-day oseltamivir course in children aged 5 years and older with influenza A, using fever duration as the primary outcome. MAIN BODY: In this multicenter, prospective, non-randomized observational cohort study, 750 children aged 5-14 years with reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A were enrolled from eight community health centers in Chongqing, China, between October 2024 and December 2025. Treatment assignment was based on guardian preference rather than randomization. The median duration of fever was shorter in the baloxavir group (22.0 h versus 40.5 h; P < 0.001). In exploratory analyses adjusted for multiple comparisons, baloxavir was associated with a shorter median time to viral clearance (24.0 h vs. 72.0 h; false discovery rate [FDR]-adjusted P < 0.001), a lower total complication rate (3.7% vs. 11.2%; FDR-adjusted P = 0.042), more rapid normalization of inflammatory markers and the CD4+/CD8 + ratio, lower revisit rate (2.1% vs. 6.9%; FDR-adjusted P = 0.003), fewer parental work-absence days (2.0 vs. 3.5 days; FDR-adjusted P < 0.001), and fewer adverse drug reactions (6.7% vs. 15.2%; FDR-adjusted P = 0.049). SHORT
conclusionIn community-dwelling children with influenza A, baloxavir marboxil was associated with more rapid fever resolution than oseltamivir. Exploratory findings suggested potential benefits regarding viral clearance, complications, healthcare utilization, and tolerability. Because treatment selection was preference-based and open-label, and because influenza A subtype and reduced-susceptibility substitutions were not evaluated, these findings should be interpreted as hypothesis-generating rather than causal.
trial registrationThis study was not prospectively registered because it was an observational study. However, the protocol was approved by the relevant ethics committee, and the study was reported following STROBE guidelines for observational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.